News

BenevolentAI at NeurIPS 2020: Machine Learning in Drug Discovery

BenevolentAI will be proudly sponsoring NeurIPS again this year. Here are the details of our activities during the week:

Network with us → Neurips Expo → Talent Pool →

Expo day: 6th December

How we leverage machine learning and AI to develop life-changing medicines - a case study with COVID-19.

The model for drug discovery and development is failing patients. It is expensive and high risk, with long research and development cycles. In this talk, we will discuss the peculiarities of machine learning across drug discovery, from the processing of scientific literature, to knowledge completion, target identification to precision medicine, to chemistry optimisation, each leveraging domain expert knowledge and state-of-the-art research and we will conclude our talk with a real example which will showcase the application of our technology and scientific expertise to repurpose existing drugs, as a potential treatment for COVID-19. 

Our Research at NeurIPS

Learning Meaningful Representations of Life workshop:

Our AI Science Intern, Constantin Schneider, will present his paper on ‘Auxiliary task evaluations to learn meaningful representations from electronic health records', co-authored by BenevolentAI's Senior Machine Learning Researcher, Hamish Tomlinson, at the Learning Meaningful Representations of Life workshop’.

Authors: Hamish Tomlinson, Constantin Schneider

Machine Learning for Molecules Workshop

Our team, will be presenting their paper on Molecular representation learning with language models and domain-relevant auxiliary tasks at the Machine Learning for Molecules Workshop

Authors: Fabian et al. (2020)

Network with our team: join us on Hopin

While you're at NeurIPS, connect with our team virtually via the Hopin platform. Connect with our team at networking sessions to ask any questions you may have, and/or join our careers with impact meetup to learn more about what we do and how we work. The full programme will be coming soon. As we have limited space, we advise you to book your spot now.

Network with us →

More Posts

You Might Also Like

Blog
Intern at BenevolentAI part I: meet our 2020 intern cohort
What impactful work did our interns get up to across Engineering, Data Science, ML and business operations this summer? Get to know them and their work in our tech internships blog.
Nov 26, 2020
News
FDA grants Emergency Use Authorisation for baricitinib in hospitalised COVID-19 patients nine months after initial hypothesis was published by BenevolentAI
BenevolentAI scientists first identified baricitinib as a potential treatment for COVID-19 in early February 2020 using Benevolent's AI tools and biomedical knowledge graph.
Nov 20, 2020
Blog
Careers with Impact: 5 learnings from machine learning applied drug discovery
Last week, we brought together four of our exceptional colleagues for a panel discussion on careers in machine learning applied drug discovery. Here are some of our main takeaways:
Nov 17, 2020
Blog
Data published in Science Advances shows baricitinib reduces COVID-19 morbidity and mortality
Research published in Science Advances supports BenevolentAI’s AI-generated hypothesis from late January for baricitinib as a treatment for COVID-19.
Nov 13, 2020
News
Sir Nigel Shadbolt joins BenevolentAI as a non-executive director
BenevolentAI strengthens its Board with the appointment of AI pioneer Sir Nigel Shadbolt as Non-Executive Director.
Nov 3, 2020
News
Rob Quinn To Join BenevolentAI As Chief Financial Officer in January 2021
We are thrilled to be welcoming Rob Quinn to the BenevolentAI team as our new Chief Finance Officer from January 2021
Oct 21, 2020